MGC Pharma targeting EU + USSR + Asia with CannEpil
- The FDA last week approved UK-based GW Pharmaceuticals’ Epidiolex, a “pure plant-derived CBD” extract shown to drastically reduce seizures in children with epileptic syndromes.
- Marking the FDA’s first-ever approval of a cannabis-derived pharmaceutical product, the DEA has 90 days (until September 23) to schedule Epidiolex, a landmark decision being carefully scrutinized by the industry at large.
- Sales of Epidiolex will effectively open the pharmaceutical CBD market; the Hemp Business Journal (a division of New Frontier Data) forecasts the drug to generate between $15 million and $30 million in sales through 2018, and $180 million in 2019.
- HBJ expects the DEA to schedule Epidiolex as a Schedule IV drug and recommend that CBD be rescheduled from a Schedule I drug.
- Continued regulatory action by the FDA is expected against illicit claims and sales of unapproved, CBD-related products marketed with unproven medical claims.
- Forums
- ASX - By Stock
- RGT
- Hint of events to follow
Hint of events to follow, page-20
-
-
- There are more pages in this discussion • 122 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RGT (ASX) to my watchlist
(20min delay)
|
|||||
Last
47.0¢ |
Change
-0.015(3.09%) |
Mkt cap ! $23.22M |
Open | High | Low | Value | Volume |
49.5¢ | 50.0¢ | 46.0¢ | $48.58K | 102.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 2500 | 41.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
48.0¢ | 5000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 2500 | 0.410 |
1 | 25000 | 0.400 |
1 | 2000 | 0.350 |
1 | 12000 | 0.340 |
1 | 2988 | 0.330 |
Price($) | Vol. | No. |
---|---|---|
0.480 | 5000 | 1 |
0.510 | 4029 | 2 |
0.570 | 2662 | 2 |
0.575 | 650 | 1 |
0.650 | 45000 | 1 |
Last trade - 15.23pm 11/10/2024 (20 minute delay) ? |
Featured News
RGT (ASX) Chart |